SA517390103B1 - طرق لتحضير بولي نوكليوتيد باستخدام تركيبات ملح كاتيون متعدد التكافؤ - Google Patents

طرق لتحضير بولي نوكليوتيد باستخدام تركيبات ملح كاتيون متعدد التكافؤ Download PDF

Info

Publication number
SA517390103B1
SA517390103B1 SA517390103A SA517390103A SA517390103B1 SA 517390103 B1 SA517390103 B1 SA 517390103B1 SA 517390103 A SA517390103 A SA 517390103A SA 517390103 A SA517390103 A SA 517390103A SA 517390103 B1 SA517390103 B1 SA 517390103B1
Authority
SA
Saudi Arabia
Prior art keywords
polynucleotide
salt
composition
nucleoside subunits
multivalent cation
Prior art date
Application number
SA517390103A
Other languages
Arabic (ar)
English (en)
Inventor
فريمشاندران اتش راميا
Original Assignee
جيرون كوربوريشن
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جيرون كوربوريشن filed Critical جيرون كوربوريشن
Publication of SA517390103B1 publication Critical patent/SA517390103B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SA517390103A 2015-04-23 2017-10-04 طرق لتحضير بولي نوكليوتيد باستخدام تركيبات ملح كاتيون متعدد التكافؤ SA517390103B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Publications (1)

Publication Number Publication Date
SA517390103B1 true SA517390103B1 (ar) 2021-07-14

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
SA517390103A SA517390103B1 (ar) 2015-04-23 2017-10-04 طرق لتحضير بولي نوكليوتيد باستخدام تركيبات ملح كاتيون متعدد التكافؤ

Country Status (36)

Country Link
US (2) US10745687B2 (enExample)
EP (1) EP3286203B1 (enExample)
JP (4) JP2018513127A (enExample)
KR (1) KR102401252B1 (enExample)
CN (2) CN107429247B (enExample)
AU (2) AU2016250576C1 (enExample)
BR (1) BR112017019627B1 (enExample)
CA (1) CA2978191C (enExample)
CL (1) CL2017002314A1 (enExample)
CO (1) CO2017009217A2 (enExample)
CY (1) CY1123197T1 (enExample)
DK (1) DK3286203T3 (enExample)
EA (1) EA035885B1 (enExample)
ES (1) ES2798270T3 (enExample)
HR (1) HRP20201218T1 (enExample)
HU (1) HUE051148T2 (enExample)
IL (1) IL254222A0 (enExample)
LT (1) LT3286203T (enExample)
MA (2) MA42569B1 (enExample)
MD (1) MD3286203T2 (enExample)
ME (1) ME03811B (enExample)
MX (1) MX383293B (enExample)
MY (1) MY187804A (enExample)
PE (2) PE20221275A1 (enExample)
PH (1) PH12017501927B1 (enExample)
PT (1) PT3286203T (enExample)
RS (1) RS60645B1 (enExample)
SA (1) SA517390103B1 (enExample)
SG (2) SG11201707893RA (enExample)
SI (1) SI3286203T1 (enExample)
SM (1) SMT202000389T1 (enExample)
TN (1) TN2017000411A1 (enExample)
TW (1) TWI736532B (enExample)
UA (1) UA124521C2 (enExample)
WO (1) WO2016172346A1 (enExample)
ZA (1) ZA201706041B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP4060345A1 (en) 2016-12-19 2022-09-21 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
US11866696B2 (en) * 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
EP3727470B1 (en) 2017-12-18 2024-11-20 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69130333T2 (de) 1990-08-31 1999-03-04 Regents Of The University Of Minnesota, Minneapolis, Minn. Harze für die Feststoff-Peptidsynthese
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
PL316434A1 (en) 1994-03-18 1997-01-06 Lynx Therapeutics Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
WO2002077184A2 (en) 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
CN101321877B (zh) * 2005-10-03 2013-04-10 应用生物系统有限责任公司 用于扩增核酸的组合物、方法和试剂盒
WO2008127305A2 (en) 2006-11-01 2008-10-23 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
ES2770638T3 (es) * 2012-06-14 2020-07-02 Life Technologies Corp Nuevas composiciones, métodos y kits para la reacción en cadena de la polimerasa (PCR)
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Also Published As

Publication number Publication date
TW201706284A (zh) 2017-02-16
EA201791753A1 (ru) 2018-04-30
CA2978191C (en) 2022-10-04
TWI736532B (zh) 2021-08-21
HUE051148T2 (hu) 2021-03-01
CL2017002314A1 (es) 2018-05-04
SG10201909816PA (en) 2019-11-28
JP2025061848A (ja) 2025-04-11
US20200339975A1 (en) 2020-10-29
BR112017019627A2 (pt) 2018-05-15
AU2016250576B2 (en) 2021-02-04
UA124521C2 (uk) 2021-10-05
AU2016250576A1 (en) 2017-09-21
KR102401252B1 (ko) 2022-05-24
AU2021202803A1 (en) 2021-06-03
CY1123197T1 (el) 2021-10-29
RS60645B1 (sr) 2020-09-30
CO2017009217A2 (es) 2018-02-20
PT3286203T (pt) 2020-07-08
ZA201706041B (en) 2020-11-25
BR112017019627B1 (pt) 2022-11-29
JP2021152079A (ja) 2021-09-30
CN113564168A (zh) 2021-10-29
AU2016250576C1 (en) 2021-05-06
NZ735042A (en) 2021-11-26
PH12017501927A1 (en) 2018-03-05
PE20171785A1 (es) 2017-12-27
CN107429247A (zh) 2017-12-01
SI3286203T1 (sl) 2020-10-30
WO2016172346A1 (en) 2016-10-27
IL254222A0 (en) 2017-10-31
MD3286203T2 (ro) 2020-08-31
MX383293B (es) 2025-03-13
PE20221275A1 (es) 2022-09-01
CN113564168B (zh) 2024-10-25
US11441144B2 (en) 2022-09-13
HK1251234A1 (en) 2019-01-25
PH12017501927B1 (en) 2022-09-02
KR20170138399A (ko) 2017-12-15
MY187804A (en) 2021-10-26
US10745687B2 (en) 2020-08-18
TN2017000411A1 (en) 2019-01-16
MA42157A (fr) 2018-02-28
SMT202000389T1 (it) 2020-09-10
SG11201707893RA (en) 2017-11-29
JP2018513127A (ja) 2018-05-24
EP3286203B1 (en) 2020-05-06
ES2798270T3 (es) 2020-12-10
EP3286203A1 (en) 2018-02-28
DK3286203T3 (da) 2020-06-02
HRP20201218T1 (hr) 2020-12-11
LT3286203T (lt) 2020-07-27
JP2022168017A (ja) 2022-11-04
EA035885B1 (ru) 2020-08-27
US20160312227A1 (en) 2016-10-27
MA42569B1 (fr) 2020-08-31
MX2017011642A (es) 2017-11-02
ME03811B (me) 2021-04-20
CA2978191A1 (en) 2016-10-27
CN107429247B (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
SA517390103B1 (ar) طرق لتحضير بولي نوكليوتيد باستخدام تركيبات ملح كاتيون متعدد التكافؤ
WO2015200650A1 (en) Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
SA113340573B1 (ar) إطار قابل للطي لملجأ
Silver et al. Cellular and molecular mechanisms of secondary hyperparathyroidism.
JP2018513127A5 (enExample)
Öberg et al. Arene–anion based arginine‐binding motif on a galactose scaffold: structure–activity relationships of interactions with arginine‐rich galectins
SA118400087B1 (ar) Dna عامل انقسام ومضاد لاحتشاد الخلية البكتيرية
Conners T) 1E MIS I MINER_.
Railway et al. The Co-operator (Sydney, NSW)-Vol. 09, No. 73 (15 May 1913)
America et al. Northern Africa
KATO et al. Vegetation and microtopography of Carex livida-growing mires near Lake Rausu, Shiretoko Peninsula, Eastern Hokkaido, Japan
Green et al. Del Mar
Harvey BOND YIELDS AS RELATED TO WHOLSALE COMMODITY PRICES
Vitali Bernardi et al. Policies of «Social, Solidarity and/or Popular Economy» in Argentina, 2001-2019
PH27007A (en) 4-ethyl-3-(substituted phenyl)-1-(3-trifluoromethylphenyl)-2-pyrrolidinone derivatives
Herald 1918-01-03 Paintsville Herald
Diyector e aF lsr
PRICE FURNITURE I
It'Ill et al. THE OLDEST LAW JOUR-NAL, IN THE UNITED STATE,-
Beard et al. An institutional analysis of partial deregulation of the Australian wheat industry under Bertrand competition.
Lee THE RENMINBI AS GAME CHANGER
Holy Roman Empire Treaty of Peace Between His Imperial and Catholick Majesty Charles VI, and His Royal Catholic Majesty Philip V, Concluded at Vienna the 30th of April 1725. Treaty of Commerce Between His Imperial and Catholick Majesty Charles VI, and His Royal Catholick Majesty Philip V, Concluded at Vienna, May 1, 1725. Treaty Between the King of Great Britain, the Most Christian King, and the King of Prussia, Made at Hanover the 3rd of September, 1725
LI et al. Design, synthesis and anticancer activity studies of oleanolic acidderivatives targeting mTOR
Quadir et al. Core-shell based nanocarriers as delivery systems for biologically active metal ions and drugs
Caredes Tax counsel's report: Tax policy-the year in review